Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data
Introduction Tick-borne encephalitis (TBE) is rapidly spreading to new areas in many parts of Europe. While vaccination remains the most effective method of protection against the disease, vaccine uptake is low in many endemic countries.Areas covered We conducted a literature search of the MEDLINE d...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2311359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141406078304256 |
|---|---|
| author | Jörg Schelling Suzanne Einmahl Ralph Torgler Carsten Schade Larsen |
| author_facet | Jörg Schelling Suzanne Einmahl Ralph Torgler Carsten Schade Larsen |
| author_sort | Jörg Schelling |
| collection | DOAJ |
| description | Introduction Tick-borne encephalitis (TBE) is rapidly spreading to new areas in many parts of Europe. While vaccination remains the most effective method of protection against the disease, vaccine uptake is low in many endemic countries.Areas covered We conducted a literature search of the MEDLINE database to identify articles published from 2018 to 2023 that evaluated the immunogenicity and effectiveness of TBE vaccines, particularly Encepur, when booster doses were administered up to 10 years apart. We searched PubMed with the MeSH terms ‘Encephalitis, Tick-Borne/prevention and control’ and ‘Vaccination’ for articles published in the English language.Expert opinion Long-term immunogenicity data for Encepur and real-world data on vaccine effectiveness and breakthrough infections following the two European TBE vaccines, Encepur and FSME-Immun, have shown that extending the booster interval from 3–5 years to 10 years does not negatively impact protection against TBE, regardless of age. Such extension not only streamlines the vaccination schedules but may also increase vaccine uptake and compliance among those living in endemic regions. |
| format | Article |
| id | doaj-art-76f4bf30ae3341938b9f49774695c6ad |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-76f4bf30ae3341938b9f49774695c6ad2024-12-04T09:49:48ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-0123122623610.1080/14760584.2024.2311359Evidence for a 10-year TBE vaccine booster interval: an evaluation of current dataJörg Schelling0Suzanne Einmahl1Ralph Torgler2Carsten Schade Larsen3Department of Medicine IV, LMU University Hospital, LMU Munich, University of Munich, Munich, GermanyDepartment of Medical Strategy, Bavarian Nordic AG, Zug, SwitzerlandDepartment of Medical Strategy, Bavarian Nordic AG, Zug, SwitzerlandDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, DenmarkIntroduction Tick-borne encephalitis (TBE) is rapidly spreading to new areas in many parts of Europe. While vaccination remains the most effective method of protection against the disease, vaccine uptake is low in many endemic countries.Areas covered We conducted a literature search of the MEDLINE database to identify articles published from 2018 to 2023 that evaluated the immunogenicity and effectiveness of TBE vaccines, particularly Encepur, when booster doses were administered up to 10 years apart. We searched PubMed with the MeSH terms ‘Encephalitis, Tick-Borne/prevention and control’ and ‘Vaccination’ for articles published in the English language.Expert opinion Long-term immunogenicity data for Encepur and real-world data on vaccine effectiveness and breakthrough infections following the two European TBE vaccines, Encepur and FSME-Immun, have shown that extending the booster interval from 3–5 years to 10 years does not negatively impact protection against TBE, regardless of age. Such extension not only streamlines the vaccination schedules but may also increase vaccine uptake and compliance among those living in endemic regions.https://www.tandfonline.com/doi/10.1080/14760584.2024.2311359TBE booster intervalTBE vaccinationTBE vaccine effectivenesstick-borne encephalitisvaccination management |
| spellingShingle | Jörg Schelling Suzanne Einmahl Ralph Torgler Carsten Schade Larsen Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data Expert Review of Vaccines TBE booster interval TBE vaccination TBE vaccine effectiveness tick-borne encephalitis vaccination management |
| title | Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data |
| title_full | Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data |
| title_fullStr | Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data |
| title_full_unstemmed | Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data |
| title_short | Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data |
| title_sort | evidence for a 10 year tbe vaccine booster interval an evaluation of current data |
| topic | TBE booster interval TBE vaccination TBE vaccine effectiveness tick-borne encephalitis vaccination management |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2311359 |
| work_keys_str_mv | AT jorgschelling evidencefora10yeartbevaccineboosterintervalanevaluationofcurrentdata AT suzanneeinmahl evidencefora10yeartbevaccineboosterintervalanevaluationofcurrentdata AT ralphtorgler evidencefora10yeartbevaccineboosterintervalanevaluationofcurrentdata AT carstenschadelarsen evidencefora10yeartbevaccineboosterintervalanevaluationofcurrentdata |